



Australian Government

Department of Health

Office of the Gene Technology Regulator

NOTIFICATION OF APPLICATION

Receipt of licence application from the Westmead Institute for Medical Research for Clinical trial with genetically modified E.coli to reduce antibiotic resistance

The Office of the Gene Technology Regulator (OGTR) has received a licence application (DIR 183) from the Westmead Institute for Medical Research to conduct a clinical trial to evaluate the safety and efficacy of GM *E.coli* to deliver genes to gut bacteria that restore sensitivity to antibiotics. A summary of the application is posted on our website under '[What's New](#)'.

The clinical trial is proposed to take place at Westmead hospitals over a period of 5 years. Up to 100 participants per year would receive the treatment.

The OGTR is preparing a Risk Assessment and Risk Management Plan for the application. This is expected to be released for public comment and advice from experts, agencies and authorities in late April 2021. There will be at least 30 days for submission of comments.

If you have any questions or would like to receive a copy of the full application or the summary, please contact the OGTR and quote the reference number DIR 183.

Office of the Gene Technology Regulator

MDP 54 GPO Box 9848 CANBERRA ACT 2601

Telephone: 1800 181 030 E-mail: ogtr@health.gov.au

[OGTR website](#)

Dr Raj Bhula
Gene Technology Regulator
08 February 2021